Literature DB >> 6553507

Inhibition of pulmonary metastases of B16 melanoma with irradiated tumor cells and BCG.

J Tai, A Guclu, T Ghose, S Norvell.   

Abstract

When the tumor-bearing leg of C57BL/6J mice was amputated 16 days after SC inoculation of 10(6)B16 melanoma cells, all the amputated mice died of pulmonary metastases. Transfer of lungs from the amputated to normal syngeneic mice revealed tumor cells in the lungs just after amputation. Repeated weekly injections of BCG and irradiated tumor cells, beginning 24 h after amputation of the tumor-bearing limb, prolonged the survival only of mice presensitized to BCG. Injections of BCG or irradiated melanoma cells alone, or neuraminidase- and mitomycin C-treated tumor cells or of Levamisole had no effect, but injections of ConA-coated tumor cells slightly prolonged the survival of the amputated mice. Both BCG and B16 cells induced humoral and cell-mediated immunity but there was no cross-reactivity between BCG and B16 cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6553507     DOI: 10.1007/bf00199461

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  22 in total

1.  Effect of size and/or rate of growth of a transplantable mouse adenocarcinoma on lung; metastasis production.

Authors:  C MARTINEZ; G MIROFF; J J BITTNER
Journal:  Cancer Res       Date:  1956-05       Impact factor: 12.701

2.  An experimental study of the relationship between tumor size and number of lung metastases.

Authors:  J S WOOD; E D HOLYOKE; W P CLASON; S C SOMMERS; S WARREN
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

3.  Tumor regression mediated by Mycobacterium bovis (strain BCG).

Authors:  B Zbar
Journal:  Natl Cancer Inst Monogr       Date:  1972-12

4.  Neuraminidase-induced enhancement of tumor growth in mice.

Authors:  G Froese; I Berczi; A H Sehon
Journal:  J Natl Cancer Inst       Date:  1974-06       Impact factor: 13.506

5.  A model for immunity to melanomas in mice.

Authors:  D R Burger; F Hu; L M Pasztor; A Malley
Journal:  Proc Soc Exp Biol Med       Date:  1973-11

6.  Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells.

Authors:  A Rios; R L Simmons
Journal:  Int J Cancer       Date:  1974-01-15       Impact factor: 7.396

7.  Comparison of effect of BCG, glucan and levamisole on B16 melanoma metastases.

Authors:  J W Proctor; B G Auclair; L Stokowski; W A Mansell; H Shibata
Journal:  Eur J Cancer       Date:  1977-02       Impact factor: 9.162

8.  Inconsistent response of B16 melanoma to BCG immunotherapy.

Authors:  J W Kreider; G L Bartlett; D M Purnell
Journal:  J Natl Cancer Inst       Date:  1976-04       Impact factor: 13.506

9.  Combination chemotherapy, radiotherapy, and BCG immunotherapy in limited small-cell carcinoma of the lung: a Southwest Oncology Group Study.

Authors:  J D McCracken; T Chen; J White; M Samson; R Stephens; C A Coltman; J Saiki; M Lane; J Bonnet; M McGavran
Journal:  Cancer       Date:  1982-06-01       Impact factor: 6.860

10.  Treatment of disseminated malignant melanoma with high-dose oral BCG.

Authors:  A D Varella; D C Bandiera; A R de Amorim; L A Calvis; I O Santos; N Escaleira; F Gentil
Journal:  Cancer       Date:  1981-09-15       Impact factor: 6.860

View more
  2 in total

1.  Activation of natural resistance against lung metastasis of an adenocarcinoma in T-cell depressed spontaneously hypertensive rats by infection with Listeria monocytogenes.

Authors:  Y Koga; J Hamada; N Takeichi; A Nakane; T Minagawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

2.  Recombinant BCG therapy suppresses melanoma tumor growth.

Authors:  R B Duda; H Yang; D D Dooley; G Abu-Jawdeh
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.